Checkpoint Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
And thank you for tuning in to the H.C. Wainwright 24th Annual Global Investment hybrid conference. My name is Trevor Levy, and I'm on the corporate access team with H.C. Wainwright. It is now my honor to introduce our speaker. Please welcome, James Oliviero, the President and CEO of Checkpoint Therapeutics.
Thanks, Trevor, and thank you to H.C. Wainwright for inviting Checkpoint to present at the conference here today. I'm James Oliviero. I'm President and CEO of Checkpoint Therapeutics, and thanks to everyone for joining me out there. Before I begin, I'd like to remind everybody that I'll be making forward-looking statements during this presentation, so I encourage anyone interested in the company to review our full SEC filings on sec.gov.
So Checkpoint Therapeutics, we are a biopharmaceutical company focused on developing novel therapies for the treatment of solid tumor cancers. Our lead development program, as you can see on the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |